Login

BVZ Holding CEO Fernando Lehner on H1 2022, Future Projects, and Motivating His Team Amidst Challenges | Fernando Lehner - CEO of bvz holding ag 00:10:00

Share On Facebook Share On Twitter

Fernando Lehner is the CEO of bvz holding ag

Recent Videos

00:10:00
Dryden Gold Secures $20M+ War Chest, Delivers High-Grade Discoveries and Expands Drill Targets Across Gold Rock District|Trey Wasser,CEO & Director,Dryden Gold
00:10:00
Mitchell Services Targets $50–60M EBITDA as Rig Utilization Drives Earnings Upside| Andrew Elf,CEO,Mitchell Services Limited
00:10:00
Lomiko Metals Reports Strong Pre-Feasibility Results with $800M NPV, Advancing High-Growth Graphite Projects|Gordana Slepcev,CEO,Lomiko Metals Inc.4
00:10:00
Generative AI Meets Wet Lab: Absci Accelerates Biologic Development with Hybrid Business Model|Sean McClain,CEO,Absci
00:10:00
Obliva Aims to Transform Lives of Children with Rare Mitochondrial Disorders|Ellen K. Donnelly ,CEO,Abliva AB7
00:10:00
Abionic Repositions Bio-HDL Therapy CCR001 for Rare Kidney and Eye Disorders with Promising Early Results|Cyrille Tupin,CEO,ABIONYX Pharma
00:10:00
Abingdon Health Reports 45% H1 Revenue Growth Amid Strategic Expansion and Large Contract Wins|Dr Chris Hand,Chairman,Abingdon Health
00:10:00
EB-101 Gene Therapy Shows Promising Results in Treating Recessive Dystrophic EB|Vishwas Seshadri,CEO,Abeona Therapeutics
00:10:00
Revolutionizing Trauma Care: How AAP’s Silver Technology is Fighting Deadly Implant Infections|Rubino Di Girolamo,CEO,aap Implantate AG
00:10:00
Revolutionizing Cancer Treatment: Tumor-Agnostic mTOR Targeting Shows Breakthrough Success in Rare and Genetic-Driven Tumors| Neil Desai, Founder, Executive Chairman ,Aadi Bioscience
00:10:00
Millions Affected, No Approved Cure: 89bio Advances New Therapy for NASH|Rohan Palekar,CEO,89bio Inc2
00:10:00
Malaria Prevention Drug Arakoda Positioned to Drive Future Growth for 60 Degrees Pharmaceuticals|Geoffrey Dow,President,60 Degrees Pharmaceuticals
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4basebio CEO Heikki Lanckriet Unveils Vision for Next-Generation Synthetic DNA and Gene Therapy Components|Heikki Lanckriet,CEO,4basebio
00:10:00
Jim Woody on Leading 180 Life Sciences: Advancing Breakthrough Biologic Therapies for Inflammation, Fibrosis, and Pain|Dr. Jim Woody,CEO,180 Life Sciences

Suggestions

00:10:00
Luis Cid Discusses Opdenergy's First Half Results and Future Growth Plans | Luis Cid , CEO ,Opdenergy holding SA.
00:10:00
Opportunities and Innovations in Financial Technology and Capital Markets.
00:10:00
From Molecular Biology to Biotech Entrepreneurship: Pioneering Antimicrobial Therapies and Novel Drug Development in Infectious Disease | Jeffrey Stei ,CEO, Cidara Therapeutics Inc.
00:10:00
Interview with Kevin McElligott, Managing Director Australia at Franco-Nevada
00:10:00
ESG Investing and Market Insights with Doug of Aristotle Credit Partners
00:10:00
Short-Term Market Losses May Occur, But Long-Term Bull Market Thesis Remains Strong: Insights from Victoria Greene of G Squared Private Wealth
00:10:00
Transforming the companies we acquire|Ramzi Musallam,CEO,Veritas Capital
00:10:00
Meet Michelle: From Math Major to Developer to Vanguard Scrum Lead - A Journey of Growth and Innovation
00:10:00
UBS Wealth Management Strategy: Beyond Disruption | Jason Chandler - Head of Wealth Management at UBS Financial Services
00:10:00
Investing in Fast Growing Companies in the world wide|Neil Mehta,member,Greenoaks
00:10:00
Granada Goldmine: Advancing Towards Near-Term Gold Production in Quebec
00:10:00
Mad Money: Aurinia Pharmaceuticals CEO: Speculative Salvation? | Peter Greenleaf, CEO, AURINIA PHARMACEUTICALS INC

© 2017 - Neuhu+